AstraZeneca‘s IMFINZI® (durvalumab) has gained FDA approval for use in adult patients with muscle-invasive bladder cancer ...

Bristol Myers Squibb has received the FDA’s green light to introduce another immunotherapy-based treatment in first-line ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

The approval of Imfinzi was granted based on results from ... 2 "With this approval, we can now offer immunotherapy treatment to people living with limited-stage small cell lung cancer, which ...

Brian’s insurer is Meritain Health, which is a subsidiary of industry giant Aetna. After Meritain rejected the initial ...

Results showed the immunotherapy combination led to a 38 ... drug conjugate designed to target the cancer protein TROP2. —Imfinzi also added perioperative treatment of muscle invasive bladder ...

After Meritain rejected the initial immunotherapy drug, Imfinzi, Brian applied for coverage of a second, similar drug, Keytruda. That, too, was denied. The McNamaras appealed the rulings.